Prosecution Insights
Last updated: November 20, 2026
Application No. 17/691,745

HETEROAROMATIC ELECTROPHILES AND METHODS OF USING THEREOF

Non-Final OA §112
Filed
Mar 10, 2022
Priority
Feb 15, 2017 — provisional 62/459,385 +2 more
Examiner
PIHONAK, SARAH
Art Unit
1627
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Ohio State University
OA Round
3 (Non-Final)
61%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allowance Rate
935 granted / 1522 resolved
+1.4% vs TC avg
Strong +42% interview lift
Without
With
+42.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
38 currently pending
Career history
1563
Total Applications
across all art units

Statute-Specific Performance

§101
2.2%
-37.8% vs TC avg
§103
39.2%
-0.8% vs TC avg
§102
10.3%
-29.7% vs TC avg
§112
23.2%
-16.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1522 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 7/28/26 has been entered. Status of Claims Claims 1-14, and 19-20 are pending as of the response filed on 7/28/26. Claims 15-18 and 21-41 have been canceled. The nonstatutory double patenting rejection over the claims of US 11492340 is withdrawn in consideration of the acceptance of the terminal disclaimer filed on 7/28/26. New rejections under 35 USC 112(b) and an objection are made, discussed below. Claims 1-14, and 19-20 were examined. Claims 5, 6, 10, and 12-14 are rejected. Claims 1-4, 7-9, and 19-20 are allowed. Claim 11 is objected to. Claim Objection Claim 11 is objected to because of the following informalities: a comma should be present between “OR” and “NR2” under the variables for “X”. Appropriate correction is required. Claim Rejections-35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 5, 6, 10, and 12-14 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 5 depends from claim 1 and recites “wherein the acetylcholinesterase”, however claim 1 doesn’t refer to acetylcholinesterase. There is insufficient antecedent basis for this limitation in the claim, and the claim is indefinite. Claim 6 depends from claim 1 and recites the option of R4 being nitrile, however, nitrile is not included as an option for R4 in claim 1. There is insufficient antecedent basis for this limitation in the claim, and the claim is indefinite. Claim 6 also recites the option of R3 and R4 being optionally present, however, claim 1 doesn’t recite these equivalent positions, corresponding to R’, to be optionally present. There is a lack of antecedent basis for these limitations. It is suggested that “optionally present” for R3 and R4 be replaced with “hydrogen” instead. Claim 10 depends directly from claim 9 and shows the positions corresponding to R4’ and R4”’ as being hydrogen; however, claim 9 doesn’t include hydrogen for these positions. There is insufficient antecedent basis for this limitation, and the claim is indefinite. Claim 12 depends from claim 1 and recites R3, R4, and R4b as being optionally present. However, claim 1 doesn’t recite the option of these positions (corresponding to R’) as being optional. There is a lack of antecedent basis for these limitations. It is suggested that “optionally present” for these variables be replaced with “hydrogen” instead. Claims 12-13 are similarly rejected as these claims depend directly from claim 12 and incorporate the same limitations as claim 12 lacking antecedent basis. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARAH PIHONAK whose telephone number is (571)270-7710. The examiner can normally be reached Monday-Friday 9:00-5:30 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached at 571-270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. SARAH . PIHONAK Primary Examiner Art Unit 1627 /SARAH PIHONAK/Primary Examiner, Art Unit 1627
Read full office action

Prosecution Timeline

Mar 10, 2022
Application Filed
Nov 15, 2024
Response after Non-Final Action
May 09, 2025
Non-Final Rejection mailed — §112
Nov 10, 2025
Response Filed
Jan 28, 2026
Final Rejection mailed — §112
Jul 28, 2026
Request for Continued Examination
Jul 29, 2026
Response after Non-Final Action
Nov 10, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788731
USE OF 3-METHYLMETHCATHINONE
6y 9m to grant Granted Nov 10, 2026
Patent 12788729
AMISELIMOD FOR PREVENTING, TREATING OR AMELIORATING ULCERATIVE COLITIS
3y 3m to grant Granted Nov 10, 2026
Patent 12790297
PROCESSES FOR THE PREPARATION OF (S)-2-(4-CHLORO-2-METHOXYPHENYL)-2-((3 -METHOXY-5-(M ETHYLSULFONYL)PHENYL)AMINO)-1 -(1H-INDOL-3-YL)ETHENONE DERIVATIVES
2y 10m to grant Granted Nov 10, 2026
Patent 12788714
AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS
2y 8m to grant Granted Nov 10, 2026
Patent 12778920
METHODS OF TREATING SJÖGRENS SYNDROME
3y 11m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
61%
Grant Probability
99%
With Interview (+42.3%)
2y 9m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1522 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month